Journal: PLOS One

Article Title: MMP-2 associated imbalance of VEGF/Endostatin is linked to suppression of the PI3K/AKT/HIF-1α pathway in steroid-induced osteonecrosis of femoral head

doi: 10.1371/journal.pone.0346880

Figure Lengend Snippet: (A) Representative immunofluorescence images showing VEGF expression in the femoral head of control and SONFH groups (scale bar = 100 μm); (B) Quantification of VEGF fluorescence intensity in control and SONFH groups; (C) Representative immunofluorescence images showing Endostatin expression in the femoral head of control and SONFH groups (scale bar = 100 μm); (D) Quantification of Endostatin fluorescence intensity in these two groups; (E) Representative Western blotting images of MMP-2 expression in the femoral head of control and SONFH groups; (F) Quantification of MMP-2 expression in these two groups. (*P < 0.05, **P < 0.01).

Article Snippet: Mice in the SONFH+MMP-2 group received subcutaneous injections of recombinant MMP-2 (10 μg/kg; MedChemExpress, NJ, USA) every three days [ , ], while those in the SONFH+Endostatin group were administered daily subcutaneous injections of recombinant Endostatin (2 mg/kg; MedChemExpress, NJ, USA) [ ].

Techniques: Immunofluorescence, Expressing, Control, Fluorescence, Western Blot

Journal: PLOS One

Article Title: MMP-2 associated imbalance of VEGF/Endostatin is linked to suppression of the PI3K/AKT/HIF-1α pathway in steroid-induced osteonecrosis of femoral head

doi: 10.1371/journal.pone.0346880

Figure Lengend Snippet: (A) Representative HE staining images of the femoral head in control, SONFH, and SONFH+Endostatin groups (scale bar = 100 μm); (B) Quantitative analysis of percentage of empty osteocyte from HE staining; (C) Representative micro-CT vascular reconstructions of the femoral head in each group; (D) Calcein staining images showing mineral apposition in each group (scale bar = 25 μm); (E) Quantitative analysis of vascular volume fraction from micro-CT angiography; (F) Quantification of mineral apposition rate (MAR) in each group. (*P < 0.05, ***P < 0.001, ****P < 0.0001).

Article Snippet: Mice in the SONFH+MMP-2 group received subcutaneous injections of recombinant MMP-2 (10 μg/kg; MedChemExpress, NJ, USA) every three days [ , ], while those in the SONFH+Endostatin group were administered daily subcutaneous injections of recombinant Endostatin (2 mg/kg; MedChemExpress, NJ, USA) [ ].

Techniques: Staining, Control, Micro-CT

Journal: PLOS One

Article Title: MMP-2 associated imbalance of VEGF/Endostatin is linked to suppression of the PI3K/AKT/HIF-1α pathway in steroid-induced osteonecrosis of femoral head

doi: 10.1371/journal.pone.0346880

Figure Lengend Snippet: (A) Relative mRNA levels of Endostatin in the femoral head tissues of each group; (B) Western blotting images showing Endostatin protein expression; (C) Quantification of Endostatin protein levels; (D) Representative immunofluorescence images of Endostatin expression; (E) Quantitative analysis of Endostatin immunofluorescence intensity. (*P < 0.05, **P < 0.01, ***P < 0.001).

Article Snippet: Mice in the SONFH+MMP-2 group received subcutaneous injections of recombinant MMP-2 (10 μg/kg; MedChemExpress, NJ, USA) every three days [ , ], while those in the SONFH+Endostatin group were administered daily subcutaneous injections of recombinant Endostatin (2 mg/kg; MedChemExpress, NJ, USA) [ ].

Techniques: Western Blot, Expressing, Immunofluorescence

Journal: World Journal of Surgical Oncology

Article Title: The efficacy and safety of a taxane-based chemotherapy regimen combined with a PD-1 inhibitor in HNSCC: a multicenter real-world study

doi: 10.1186/s12957-024-03644-7

Figure Lengend Snippet: The efficacy assessment of 154 cases of recurrent/metastatic head and neck squamous cell carcinoma patients treated with first-line PD-1 inhibitors in combination with a taxane-based chemotherapy

Article Snippet: China International Medical Exchange Foundation, Simcere Anti-Tumor Special Fund Clinical Project, Intratumoral Injection of Recombinant Human Endostatin Combined with Chemotherapy for the Treatment of Exophytic Recurrent and Metastatic Malignant Tumors of the Head and Neck, Registration Number: ChiCTR1900022364; Project Number: Z-2014-06-18384.

Techniques:

Journal: World Journal of Surgical Oncology

Article Title: The efficacy and safety of a taxane-based chemotherapy regimen combined with a PD-1 inhibitor in HNSCC: a multicenter real-world study

doi: 10.1186/s12957-024-03644-7

Figure Lengend Snippet: The progression-free survival rate of 154 cases of recurrent/metastatic head and neck squamous cell carcinoma patients treated with first-line PD-1 inhibitors in combination with a taxane-based chemotherapy

Article Snippet: China International Medical Exchange Foundation, Simcere Anti-Tumor Special Fund Clinical Project, Intratumoral Injection of Recombinant Human Endostatin Combined with Chemotherapy for the Treatment of Exophytic Recurrent and Metastatic Malignant Tumors of the Head and Neck, Registration Number: ChiCTR1900022364; Project Number: Z-2014-06-18384.

Techniques:

Journal: World Journal of Surgical Oncology

Article Title: The efficacy and safety of a taxane-based chemotherapy regimen combined with a PD-1 inhibitor in HNSCC: a multicenter real-world study

doi: 10.1186/s12957-024-03644-7

Figure Lengend Snippet: The overall survival rate of 154 cases of recurrent/metastatic head and neck squamous cell carcinoma patients treated with first-line PD-1 inhibitors in combination with a taxane-based chemotherapy

Article Snippet: China International Medical Exchange Foundation, Simcere Anti-Tumor Special Fund Clinical Project, Intratumoral Injection of Recombinant Human Endostatin Combined with Chemotherapy for the Treatment of Exophytic Recurrent and Metastatic Malignant Tumors of the Head and Neck, Registration Number: ChiCTR1900022364; Project Number: Z-2014-06-18384.

Techniques:

Journal: World Journal of Surgical Oncology

Article Title: The efficacy and safety of a taxane-based chemotherapy regimen combined with a PD-1 inhibitor in HNSCC: a multicenter real-world study

doi: 10.1186/s12957-024-03644-7

Figure Lengend Snippet: Kaplan-meier curves for univariate analysis of clinical characteristics in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with pd-1 inhibitors in combination with a taxane-based chemotherapy. Note (A) : Comparison of PFS survival curves based on the presence or absence of distant metastasis; (B) : Comparison of OS survival curves based on the presence or absence of distant metastasis; (C) : Comparison of PFS survival curves based on whether subsequent radiotherapy was administered; (D) : Comparison of OS survival curves based on whether subsequent radiotherapy was administered; (E): Comparison of PFS survival curves based on whether radiotherapy was administered before recurrence/metastasis; (F) : Comparison of OS survival curves based on whether radiotherapy was administered before recurrence/metastasis;

Article Snippet: China International Medical Exchange Foundation, Simcere Anti-Tumor Special Fund Clinical Project, Intratumoral Injection of Recombinant Human Endostatin Combined with Chemotherapy for the Treatment of Exophytic Recurrent and Metastatic Malignant Tumors of the Head and Neck, Registration Number: ChiCTR1900022364; Project Number: Z-2014-06-18384.

Techniques: Comparison

Journal: World Journal of Surgical Oncology

Article Title: The efficacy and safety of a taxane-based chemotherapy regimen combined with a PD-1 inhibitor in HNSCC: a multicenter real-world study

doi: 10.1186/s12957-024-03644-7

Figure Lengend Snippet: Multifactorial analysis of progression-free survival in 154 cases of recurrent/metastatic squamous cell carcinoma of the head and neck treated with first-line pd-1 inhibitors combined with a taxane-based chemotherapy

Article Snippet: China International Medical Exchange Foundation, Simcere Anti-Tumor Special Fund Clinical Project, Intratumoral Injection of Recombinant Human Endostatin Combined with Chemotherapy for the Treatment of Exophytic Recurrent and Metastatic Malignant Tumors of the Head and Neck, Registration Number: ChiCTR1900022364; Project Number: Z-2014-06-18384.

Techniques:

Journal: World Journal of Surgical Oncology

Article Title: The efficacy and safety of a taxane-based chemotherapy regimen combined with a PD-1 inhibitor in HNSCC: a multicenter real-world study

doi: 10.1186/s12957-024-03644-7

Figure Lengend Snippet: Multifactorial analysis of overall survival in 154 cases of recurrent/metastatic squamous cell carcinoma of the head and neck treated with first-line pd-1 inhibitors combined with a taxane-based chemotherapy

Article Snippet: China International Medical Exchange Foundation, Simcere Anti-Tumor Special Fund Clinical Project, Intratumoral Injection of Recombinant Human Endostatin Combined with Chemotherapy for the Treatment of Exophytic Recurrent and Metastatic Malignant Tumors of the Head and Neck, Registration Number: ChiCTR1900022364; Project Number: Z-2014-06-18384.

Techniques:

Journal: BMC Cancer

Article Title: Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy

doi: 10.1186/s12885-024-12001-6

Figure Lengend Snippet: The efficacy of endostar with NSCLC in previously reported studies

Article Snippet: Recombinant human endostatin (Endostar): In the CCRT + Endostar group, the administered dose of Endostar (Shandong Simcere-Medgenn Bio-pharmaceutical Co., LTD., trade name: Endostar, Sinopharm approved S20050088) was 7.5 mg/m 2 /day with 1–14 days of continuous administration.

Techniques: Control

Journal: MedComm – Oncology

Article Title: Combining an adenovirus encoding human endostatin and PD‐1 blockade enhanced antitumor immune activity

doi: 10.1002/mog2.21

Figure Lengend Snippet: FIGURE 2 Ad‐E improved antitumor activity in vivo. (A) In the B16F10 model, mice in the Ad‐Null and Ad‐E groups were intratumorally injected with 1 × 109 pfu empty adenovirus (Ad‐Null) or recombinant adenovirus expressing endostatin (Ad‐E), respectively, every 3 days for four injection in total. Mice in the control group received sterile saline. Data are representative of at least two independent experiments. (B) In the MC38 model, an adenovirus was intratumorally injected at a dose of 3 × 108 pfu once a week for 2 weeks. Data are representative of at least two independent experiments. (C) In the B16F10 model, 3 days after the last dose of Ad‐E therapy, mice (n = 3) were killed, and tumors were processed to analyze the proportions of CD4+ and CD8+ T cells. (D) PD‐L1 mRNA expression in tumors were detected by RT‐qPCR. *p < 0.05. **p < 0.01. ***p < 0.001. mRNA, messenger RNA; RT‐qPCR, quantitative real‐time polymerase chain reaction.

Article Snippet: Among the treatment protocols, empty adenoviral vectors or the recombinant adenovirus expressing endostatin was intratumorally injected at a dose of 3 × 108 pfu once a week for 2 weeks in the MC38 model or at 1 × 109 pfu twice a week for 2 weeks in the B16F10 model. IgG2a or an anti‐PD‐1 (αPD‐1) mAb (both from Bio X Cell) was intraperitoneally injected at a dose of 200 μg twice a week for 2 weeks in both MC38 and B16F10 tumor models.

Techniques: Activity Assay, In Vivo, Injection, Recombinant, Expressing, Control, Sterility, Saline, Quantitative RT-PCR, Real-time Polymerase Chain Reaction

Journal: Signal Transduction and Targeted Therapy

Article Title: Targeting integrin pathways: mechanisms and advances in therapy

doi: 10.1038/s41392-022-01259-6

Figure Lengend Snippet: Integrin-targeting therapies in clinical trials

Article Snippet: Pegylated recombinant human endostatin , NCT01527864 , Protgen Ltd , Peptide , 2012-02-07 , α5β1 , Non-small cell lung cancer , 10 mg/m 2 QW , IV , Phase II.

Techniques: Recombinant, Methylation, Injection, Imaging, Biomarker Discovery, Cream, Ointment, Synthesized